plaque psoriasis
Dermatology · 2005–2026
87decisions
21medicines
31carried consumer input
120individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tildrakizumab Continuing treatment of adults with severe chronic plaque psoriasis who have achieved at least a PASI75 response with tildrakizumab 100 mg. | Mar 2026 | Recommended | no section in document |
| ustekinumab Treatment of adult patients with severe chronic plaque psoriasis and severe psoriatic arthritis. | Mar 2026 | Recommended | no section in document |
| adalimumab Treatment of immune-mediated inflammatory diseases (IMIDs) in paediatric patients under 18 years of age, with disease severity considered sufficient to cause… | Jul 2025 | Recommended with restriction | 6 individuals |
| calcipotriol with betamethasone dipropionate Chronic stable plaque type psoriasis vulgaris in adult patients inadequately controlled by potent topical corticosteroid monotherapy. | Jul 2025 | Recommended with restriction | none received |
| etanercept Severe psoriatic arthritis, ankylosing spondylitis, severe active rheumatoid arthritis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2025 | Recommended with restriction | none received |
| infliximab Multiple indications including rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults and children (6 to 17 years), refractory Crohn's disease,… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| guselkumab Treatment of adults with severe chronic plaque psoriasis. | May 2025 | Recommended with restriction | input received |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing… | Mar 2025 | Recommended with restriction | input received |
| infliximab Amendment to restriction level for continuing treatment of severe active rheumatoid arthritis, severe Crohn disease, severe chronic plaque psoriasis, severe… | Mar 2025 | Recommended with restriction | input received |
| bimekizumab Treatment of severe chronic plaque psoriasis in adult patients as a single 320 mg injection administered subcutaneously at weeks 0, 4, 8, 12, 16 and every 8… | Nov 2025 | Recommended | no section in document |
| calcipotriol with betamethasone dipropionate Treatment of chronic stable plaque type psoriasis vulgaris, including scalp psoriasis and mild to moderate plaque psoriasis on the body in adults, when… | Nov 2025 | Recommended | input received |
| ustekinumab Treatment of paediatric severe chronic plaque psoriasis, severe Crohn disease, moderate to severe ulcerative colitis, and complex refractory fistulising Crohn… | Mar 2024 | Recommended | input received Colitis Australia |
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, and complex refractory fistulising Crohn disease. | Nov 2024 | Recommended | input received Colitis Australia |
| calcipotriol with betamethasone dipropionate Chronic stable plaque type psoriasis vulgaris affecting 5–30% of body surface area, inadequately controlled by potent topical corticosteroid monotherapy. | Jul 2023 | Not recommended | input received |
| bimekizumab Treatment of severe chronic plaque psoriasis in adult patients who have failed to achieve an adequate response with at least two prior therapies. | Mar 2023 | Recommended with restriction | input received Psoriasis Australia |
| deucravacitinib Treatment of severe chronic plaque psoriasis in patients who have not responded to or have a contraindication or demonstrated intolerance to methotrexate. | Mar 2023 | Recommended with restriction | input received Creaky Joints Australia |
| tildrakizumab Treatment of severe chronic plaque psoriasis in adult patients enrolled in new clinical trials, via a grandfathering restriction to allow transition from… | Mar 2023 | Not recommended | input received |
| apremilast Severe chronic plaque psoriasis in patients who have failed treatment with, or who are contraindicated or intolerant to, methotrexate. | Nov 2023 | Recommended | input received |
| risankizumab Severe chronic plaque psoriasis in adult patients (18 years or older) who are candidates for phototherapy or systemic therapy. | Nov 2023 | Recommended with restriction | unclear |
| ustekinumab Treatment of patients with Crohn disease and severe chronic plaque psoriasis requiring a 90 mg dose of ustekinumab, in a pre-filled syringe formulation. | Jul 2022 | Recommended | none received |
| apremilast Severe chronic plaque psoriasis in patients who have failed treatment with, or who are contraindicated or intolerant to, methotrexate. | Mar 2022 | Recommended | input received Creaky Joints Australia · Global Healthy Living Foundation Australia |
| bimekizumab Treatment of severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. | Mar 2022 | Recommended with restriction | input received |
| infliximab Treatment of ankylosing spondylitis, severe chronic plaque psoriasis, severe active psoriatic arthritis, and complex refractory fistulising Crohn's disease via… | Mar 2022 | Recommended with restriction | unclear |
| risankizumab Extension of existing PBS listings for risankizumab to allow patients enrolled in the risankizumab open label extension trial (M15-997) to be grandfathered… | Mar 2022 | Recommended with restriction | none received |
| adalimumab Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, chronic plaque psoriasis, ulcerative colitis, Crohn's disease, and… | Nov 2022 | Not recommended | 1 individuals |
| etanercept Listing of etanercept injection 50 mg in 1 mL single use dose-dispenser cartridges for the same indications as currently listed etanercept pre-filled syringes:… | Jul 2021 | Recommended with restriction | unclear |
| guselkumab Treatment of severe chronic plaque psoriasis (CPP) in adults. The pre-filled pen formulation is a new presentation of the existing guselkumab pre-filled… | Mar 2021 | Not recommended | input received |
| ustekinumab Treatment of paediatric patients with severe chronic plaque psoriasis (CPP) who have failed to achieve adequate response to at least 2 of 3 systemic treatments… | Mar 2021 | Recommended | 1 individuals |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile idiopathic arthritis. | Nov 2021 | Recommended | unclear |
| risankizumab Treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy. | Nov 2021 | Recommended | none received |
| secukinumab Treatment of severe chronic plaque psoriasis in paediatric patients under 18 years of age who have failed to achieve adequate response to at least 2 of 3… | Nov 2021 | Recommended with restriction | input received |
| biologics (etanercept, infliximab, adalimumab, ustekinumab, secukinumab, ixekizumab, guselkumab, tildrakizumab) Chronic plaque psoriasis in patients with baseline PASI ≥ 12 to ≤ 15 who have failed to achieve adequate response to at least two conventional therapies… | Jul 2020 | Noted | no section in document |
| guselkumab Treatment of severe chronic plaque psoriasis in adult patients (18 years or older) who are candidates for systemic therapy or phototherapy. | Jul 2020 | Recommended | none received |
| apremilast Severe chronic plaque psoriasis in patients who have failed treatment with, or are contraindicated/intolerant to methotrexate. | Jul 2020 | Recommended with restriction | input received |
| etanercept Support for uptake of etanercept biosimilar (Brenzys) in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic plaque… | Dec 2020 | Not recommended | no section in document |
| infliximab Treatment of adults with severe active rheumatoid arthritis, ankylosing spondylitis, severe refractory Crohn's disease, complex refractory fistulising Crohn's… | Nov 2020 | Recommended with restriction | input received Colitis Australia · Parallel- Group |
| risankizumab Severe chronic plaque psoriasis in adults who have failed or are contraindicated to conventional therapy. | Jul 2019 | Recommended with restriction | input received |
| certolizumab pegol Treatment of severe chronic plaque psoriasis in adult patients meeting specified PBS criteria who have failed to achieve adequate response to non-biologic… | Mar 2019 | Recommended with restriction | none received |
| infliximab Subsequent continuing treatment for severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe Crohn disease, moderate to severe… | Mar 2019 | Recommended with restriction | 3 individuals |
| certolizumab pegol Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. | Nov 2019 | Not recommended | none received |
| adalimumab Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile idiopathic arthritis, severe… | Jul 2018 | Recommended | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| tildrakizumab Treatment of severe chronic plaque psoriasis in adult patients who have failed conventional therapy and meet PBS criteria. | Jul 2018 | Recommended with restriction | none received |
| apremilast Moderate to severe plaque psoriasis in adults who have failed to achieve an adequate response to methotrexate. | Mar 2018 | Not recommended | 2 individuals |
| calcipotriol with betamethasone dipropionate Chronic stable plaque type psoriasis vulgaris with varying body surface area involvement (7-13%, 13-19%, or >20%), inadequately controlled by potent topical… | Mar 2018 | Not recommended | none received |
| etanercept Biosimilar etanercept for multiple indications including severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic… | Mar 2018 | Recommended with restriction | none received |
| guselkumab Treatment of severe chronic plaque psoriasis in adult patients who have failed conventional systemic therapy. | Mar 2018 | Recommended with restriction | 5 individuals |
| etanercept Proposed changes to the listing of etanercept (Brenzys brand) to support biosimilar uptake, including changes to authority requirements and treatment cycle… | Nov 2018 | Deferred | none received |
| etanercept severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, and severe chronic plaque psoriasis | Aug 2017 | Recommended with restriction | no section in document |
| secukinumab Continuing treatment of severe chronic plaque psoriasis that is refractory to treatment with non-biological disease modifying anti-rheumatic drugs (DMARDs). | Jul 2017 | Not recommended | none received |
| apremilast Moderate-to-severe plaque psoriasis in patients who have failed to achieve an adequate response or are contraindicated to treatment with methotrexate. | Mar 2017 | Not recommended | none received |
| infliximab Change to initial and continuing treatment restrictions for the biosimilar brand of infliximab (Renflexis) for severe active rheumatoid arthritis, ankylosing… | Nov 2017 | Recommended with restriction | none received |
| apremilast Treatment of moderate to severe plaque psoriasis in adults. Indicated for use after failure of methotrexate therapy. | Nov 2017 | Deferred | 72 individuals |
| ixekizumab Treatment of severe chronic plaque psoriasis that is refractory to treatment with non-biological DMARDs. | Jul 2016 | Recommended with restriction | input received |
| etanercept Biosimilar to etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended | input received |
| secukinumab Treatment of chronic plaque psoriasis. This submission sought to amend the PBS restriction to allow an increase in maximum quantity to cover the loading dose… | Mar 2016 | Recommended | no section in document |
| apremilast Treatment of moderate-to-severe plaque psoriasis in adults. Resubmission for Authority Required (Streamlined) listing as a treatment option in the same line of… | Nov 2016 | Not recommended | 27 individuals Psoriasis Australia |
| calcipotriol with betamethasone dipropionate Treatment of chronic stable plaque type psoriasis vulgaris in adults inadequately controlled with either a vitamin D analogue or potent topical corticosteroid… | Nov 2016 | Recommended with restriction | none received |
| infliximab Biosimilar to Remicade for multiple indications including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and… | Nov 2016 | Recommended | none received |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| apremilast Treatment of moderate-to-severe plaque psoriasis in patients who have previously received and failed to achieve an adequate response to one or more systemic… | Mar 2015 | Not recommended | none received |
| secukinumab Treatment of severe chronic plaque psoriasis which is refractory to treatment with non-biological disease modifying anti-rheumatic drugs (DMARDs) in patients… | Mar 2015 | Recommended | none received |
| calcipotriol + betamethasone dipropionate Chronic stable plaque type psoriasis vulgaris in patients not adequately controlled with either a vitamin D analogue or potent topical corticosteroid… | Nov 2015 | Recommended with restriction | none received |
| coal tar prepared Treatment of psoriasis. Scytera® Foam provides coal tar in a foam formulation designed to improve patient adherence through easier application and cosmetic… | Nov 2014 | Recommended | none received |
| adalimumab Treatment of moderate whole-body chronic plaque psoriasis in patients with PASI or DLQI >10 but PASI ≤15 who have failed 2 prior systemic therapies. | Mar 2013 | Not recommended | unclear |
| etanercept treatment of severe chronic plaque psoriasis in patients under the age of 18 years | Mar 2012 | Recommended with restriction | unclear |
| calcipotriol with betamethasone dipropionate, ointment chronic stable plaque type psoriasis vulgaris in patients not adequately controlled with either calcipotriol or potent topical corticosteroid monotherapy | Jul 2009 | Recommended with restriction | no section in document |
| adalimumab treatment of severe chronic plaque psoriasis | Mar 2009 | Recommended with restriction | no section in document |
| etanercept chronic plaque psoriasis | Mar 2009 | Recommended with restriction | no section in document |
| ustekinumab Treatment of severe chronic plaque psoriasis in patients who meet PBS criteria for treatment with a biologic. | Nov 2009 | Recommended with restriction | no section in document |
| adalimumab treatment of severe chronic plaque psoriasis | Jul 2008 | Not recommended | no section in document |
| etanercept patients with severe chronic plaque psoriasis | Jul 2008 | Recommended | no section in document |
| adalimumab Treatment of severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. | Jul 2008 | Not recommended | no section in document |
| etanercept Modification of PBS listing restrictions for severe chronic plaque psoriasis to allow extended initial treatment period (24 weeks) for PASI 50 responders and… | Jul 2008 | Recommended | no section in document |
| efalizumab Extension of initial treatment phase from 12 to 24 weeks for chronic plaque psoriasis in patients who achieve a PASI over 50 and less than 75 at 12 weeks. | Nov 2008 | Recommended with restriction | no section in document |
| tazarotene chronic stable plaque type psoriasis vulgaris | Jul 2007 | Not recommended | no section in document |
| tazarotene Chronic stable plaque type psoriasis vulgaris. | Jul 2007 | Not recommended | no section in document |
| etanercept treatment for severe chronic plaque psoriasis | Mar 2007 | Not recommended | no section in document |
| infliximab treatment of severe chronic plaque psoriasis in patients who meet certain criteria | Jul 2006 | Recommended with restriction | no section in document |
| etanercept severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy (TGA-registered indication) | Mar 2006 | Recommended with restriction | no section in document |
| coal tar prepared Treatment of chronic psoriasis. Exorex is a 1% coal tar emulsion preparation registered for relief of symptoms of psoriasis of the skin and scalp. | Jul 2005 | Recommended | no section in document |
| efalizumab Treatment of adults with severe chronic plaque psoriasis who have failed to achieve an adequate response to, or are contraindicated to at least two systemic… | Jul 2005 | Not recommended | no section in document |
| etanercept Severe chronic plaque psoriasis in adults unresponsive to, contraindicated to, or intolerant to conventional psoriasis therapies. | Jul 2005 | Not recommended | no section in document |
| efalizumab Treatment of severe chronic plaque psoriasis in a population who have been described as ‘high needs’ patients ie with refractory psoriasis. | Nov 2005 | Recommended with restriction | no section in document |
| alefacept Treatment of severe chronic plaque psoriasis in adult patients with PASI score ≥15 who are refractory, intolerant or contraindicated to currently available… | Nov 2005 | Not recommended | no section in document |
| alefacept Treatment of severe chronic plaque psoriasis in adult patients with PASI score ≥15 who are refractory, intolerant or contraindicated to currently available… | Nov 2005 | Not recommended | no section in document |
| efalizumab Treatment of severe chronic plaque psoriasis in adult patients with refractory disease who have failed at least two systemic therapies and have a PASI score… | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Colitis Australia · Psoriasis Australia · Creaky Joints Australia · Global Healthy Living Foundation Australia · Parallel- Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 31 of 64 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.